The Blood Cancer Drugs Market is expected to register a CAGR of 7% from 2025 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.
The Blood Cancer Drugs Market report covers segmental analysis by Blood Cancer Types (Leukemia, Lymphoma, Myeloma); Drugs (Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), Others); Treatment Approaches (Chemotherapeutic, MAbs/Targeted Therapies, Immunotherapeutic), and Geography (North America, Europe, Asia Pacific, and South and Central America). The global analysis is further broken down at the regional level and major countries. The report Offers the Value in US$ for the above analysis and segments.
Purpose of the ReportThe report Blood Cancer Drugs Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Blood Cancer Drugs Market Segmentation
Blood Cancer Types- Leukemia
- Lymphoma
- Myeloma
- Rituaxan/Mabthera
- Gleevac/Glivec
- Revlimid
- Velcade
- Tasigna
- Pomalyst
- Vidaza
- Kyprolis
- Adcetris
- Chemotherapeutic
- MAbs/Targeted Therapies
- Immunotherapeutic
Strategic Insights
Blood Cancer Drugs Market Growth Drivers- Improved Awareness and Early Detection: The rise in awareness about blood cancer symptoms and the importance of early diagnosis has contributed to the growing demand for blood cancer drugs. As early detection improves, more patients are diagnosed at treatable stages, which boosts the demand for effective blood cancer therapies. Public awareness campaigns and better diagnostic tools are vital factors encouraging people to seek timely medical intervention, thus accelerating the market for blood cancer drugs.
- Expanding Oncology Drug Pipelines: Pharmaceutical companies are continuously expanding their oncology drug pipelines to address various types of blood cancers. The development of next-generation therapies, including immunotherapies, combination treatments, and novel small molecule drugs, is propelling market growth. This ongoing innovation ensures that patients have access to a diverse range of effective blood cancer drugs, which is expected to contribute significantly to market expansion.
- Increase in Personalized Medicine: Personalized or precision medicine is transforming the landscape of blood cancer treatment by tailoring drugs to the genetic makeup of individual patients. With advancements in genomic sequencing and biomarker identification, therapies can now be customized to achieve optimal results. This growing trend of personalized medicine in blood cancer treatments is a significant factor driving the market, as it provides more effective, individualized treatment options that improve patient outcomes.
- Next-Generation Immunotherapies: Immunotherapy will continue to be a driving force in the Blood Cancer Drugs Market, with next-generation therapies on the horizon. These include novel immune checkpoint inhibitors, bispecific antibodies, and engineered T-cell therapies that promise to be even more potent in attacking blood cancers. With continuous research and clinical trials focused on overcoming existing limitations such as resistance and relapse, these next-gen therapies are expected to redefine the market by providing patients with more durable and long-lasting responses.
- Adoption of Precision Medicine and Biomarker-Driven Treatments: Precision medicine will see even greater adoption in the Blood Cancer Drugs Market. The future will witness an explosion in the use of genetic profiling and biomarker-driven treatments, enabling drugs to be tailored to the unique genetic characteristics of each patient's blood cancer. This approach will not only enhance the effectiveness of therapies but also minimize side effects by targeting specific mutations that drive cancer progression. The market is expected to see an increasing number of blood cancer drugs being developed with genetic testing and biomarkers in mind, further emphasizing the shift towards individualized treatment regimens.
- Enhanced Treatment for Relapsed and Refractory Blood Cancers: One of the future trends in the Blood Cancer Drugs Market is the increased focus on relapsed and refractory blood cancers. These types of cancers, which do not respond well to initial treatments, remain a significant challenge. However, new drug classes, such as novel immunotherapies, bispecific T-cell engagers, and next-gen CAR-T therapies, are poised to provide solutions. With more advanced treatment options in development, patients with difficult-to-treat blood cancers will benefit from therapies that offer improved outcomes, reducing the risk of recurrence and improving survival rates.
- Increasing Public and Private Investments in Cancer Research: The continuous flow of investments from both private and public sectors into cancer research presents a significant opportunity for the Blood Cancer Drugs Market. With governments and private organizations prioritizing cancer treatment innovation, especially in areas like precision medicine, AI-driven drug discovery, and biologics, the research landscape for blood cancers is expanding rapidly. Companies involved in the development of novel blood cancer drugs can benefit from these funding opportunities, speeding up clinical trials and the commercialization of innovative therapies.
- Increased Focus on Rare and Hard-to-Treat Blood Cancers: There is a growing opportunity within the Blood Cancer Drugs Market to focus on rare and hard-to-treat blood cancers, such as certain forms of leukemia, myeloma, and rare lymphomas. These cancers often have limited treatment options and poor prognosis, making them a priority for innovation. Developing drugs specifically designed to treat these rare conditions can create a niche market with high unmet need. As pharmaceutical companies focus on these underserved areas, they can establish themselves as leaders in developing effective therapies that significantly improve patient outcomes.
- Regulatory Expediting and Fast-Tracking of Cancer Therapies: Many regulatory bodies, such as the FDA and EMA, are increasingly expediting the approval processes for promising cancer therapies through mechanisms like the “Breakthrough Therapy” designation. This creates an opportunity for companies to bring their blood cancer drugs to market faster. Regulatory agencies are also more open to approving treatments based on early-stage clinical trial data, accelerating patient access to new therapies. This shift in regulatory dynamics enables pharmaceutical companies to capitalize on the faster approval and commercialization of cutting-edge blood cancer drugs.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Blood Cancer Drugs Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Blood Cancer Drugs Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The Blood Cancer Drugs Market is expected to register a CAGR of 7% from 2025-2031.
The major factors impacting the Blood Cancer Drugs Market are: Improved Awareness and Early Detection, Expanding Oncology Drug Pipelines and Increase in Personalized Medicine
Key future trends in this market are - Next-Generation Immunotherapies, Adoption of Precision Medicine and Biomarker-Driven Treatments and Enhanced Treatment for Relapsed and Refractory Blood Cancers
Key companies of this market are: Johnson & Johnson Inc., Amgen Inc., Bayer AG., Pfizer, Inc., AbbVie Inc., Roche Holding AG., Celgene Corporation, AstraZeneca, Novartis AG, GlaxoSmithKline PLC
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
Some of the customization options available based on request are additional 3–5 company profiles and country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Blood Cancer Drugs Market- - By Blood Cancer Types
1.3.2 Blood Cancer Drugs Market- - By Drugs
1.3.3 Blood Cancer Drugs Market- - By Treatment Approaches
1.3.4 Blood Cancer Drugs Market- - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. BLOOD CANCER DRUGS MARKET- LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. BLOOD CANCER DRUGS MARKET- - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. BLOOD CANCER DRUGS MARKET- - GLOBAL MARKET ANALYSIS
6.1. BLOOD CANCER DRUGS - GLOBAL MARKET OVERVIEW
6.2. BLOOD CANCER DRUGS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. BLOOD CANCER DRUGS MARKET- - REVENUE AND FORECASTS TO 2028 - BLOOD CANCER TYPES
7.1. OVERVIEW
7.2. BLOOD CANCER TYPES MARKET FORECASTS AND ANALYSIS
7.3. LEUKEMIA
7.3.1. Overview
7.3.2. Leukemia Market Forecast and Analysis
7.4. LYMPHOMA
7.4.1. Overview
7.4.2. Lymphoma Market Forecast and Analysis
7.5. MYELOMA
7.5.1. Overview
7.5.2. Myeloma Market Forecast and Analysis
8. BLOOD CANCER DRUGS MARKET- - REVENUE AND FORECASTS TO 2028 - DRUGS
8.1. OVERVIEW
8.2. DRUGS MARKET FORECASTS AND ANALYSIS
8.3. RITUAXAN/MABTHERA (RITUXIMAB)
8.3.1. Overview
8.3.2. Rituaxan/Mabthera (Rituximab) Market Forecast and Analysis
8.4. GLEEVAC/GLIVEC (IMATINIB)
8.4.1. Overview
8.4.2. Gleevac/Glivec (Imatinib) Market Forecast and Analysis
8.5. REVLIMID (LENALIDOMIDE)
8.5.1. Overview
8.5.2. Revlimid (Lenalidomide) Market Forecast and Analysis
8.6. VELCADE (BORTEZOMIB)
8.6.1. Overview
8.6.2. Velcade (Bortezomib) Market Forecast and Analysis
8.7. TASIGNA (NILOTINIB)
8.7.1. Overview
8.7.2. Tasigna (Nilotinib) Market Forecast and Analysis
8.8. POMALYST (POMALIDOMIDE)
8.8.1. Overview
8.8.2. Pomalyst (Pomalidomide) Market Forecast and Analysis
8.9. VIDAZA (AZACITIDINE)
8.9.1. Overview
8.9.2. Vidaza (Azacitidine) Market Forecast and Analysis
8.10. KYPROLIS (CARFILZOMIB)
8.10.1. Overview
8.10.2. Kyprolis (Carfilzomib) Market Forecast and Analysis
8.11. ADCETRIS (BRENTUXIMAB VEDOTIN)
8.11.1. Overview
8.11.2. Adcetris (Brentuximab Vedotin) Market Forecast and Analysis
8.12. OTHERS
8.12.1. Overview
8.12.2. Others Market Forecast and Analysis
9. BLOOD CANCER DRUGS MARKET- - REVENUE AND FORECASTS TO 2028 - TREATMENT APPROACHES
9.1. OVERVIEW
9.2. TREATMENT APPROACHES MARKET FORECASTS AND ANALYSIS
9.3. CHEMOTHERAPEUTIC
9.3.1. Overview
9.3.2. Chemotherapeutic Market Forecast and Analysis
9.4. MABS/TARGETED THERAPIES
9.4.1. Overview
9.4.2. MAbs/Targeted Therapies Market Forecast and Analysis
9.5. IMMUNOTHERAPEUTIC
9.5.1. Overview
9.5.2. Immunotherapeutic Market Forecast and Analysis
10. BLOOD CANCER DRUGS MARKET- REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Blood Cancer Drugs Market- Overview
10.1.2 North America Blood Cancer Drugs Market- Forecasts and Analysis
10.1.3 North America Blood Cancer Drugs Market- Forecasts and Analysis - By Blood Cancer Types
10.1.4 North America Blood Cancer Drugs Market- Forecasts and Analysis - By Drugs
10.1.5 North America Blood Cancer Drugs Market- Forecasts and Analysis - By Treatment Approaches
10.1.6 North America Blood Cancer Drugs Market- Forecasts and Analysis - By Countries
10.1.6.1 United States Blood Cancer Drugs Market-
10.1.6.1.1 United States Blood Cancer Drugs Market- by Blood Cancer Types
10.1.6.1.2 United States Blood Cancer Drugs Market- by Drugs
10.1.6.1.3 United States Blood Cancer Drugs Market- by Treatment Approaches
10.1.6.2 Canada Blood Cancer Drugs Market-
10.1.6.2.1 Canada Blood Cancer Drugs Market- by Blood Cancer Types
10.1.6.2.2 Canada Blood Cancer Drugs Market- by Drugs
10.1.6.2.3 Canada Blood Cancer Drugs Market- by Treatment Approaches
10.1.6.3 Mexico Blood Cancer Drugs Market-
10.1.6.3.1 Mexico Blood Cancer Drugs Market- by Blood Cancer Types
10.1.6.3.2 Mexico Blood Cancer Drugs Market- by Drugs
10.1.6.3.3 Mexico Blood Cancer Drugs Market- by Treatment Approaches
10.2. EUROPE
10.2.1 Europe Blood Cancer Drugs Market- Overview
10.2.2 Europe Blood Cancer Drugs Market- Forecasts and Analysis
10.2.3 Europe Blood Cancer Drugs Market- Forecasts and Analysis - By Blood Cancer Types
10.2.4 Europe Blood Cancer Drugs Market- Forecasts and Analysis - By Drugs
10.2.5 Europe Blood Cancer Drugs Market- Forecasts and Analysis - By Treatment Approaches
10.2.6 Europe Blood Cancer Drugs Market- Forecasts and Analysis - By Countries
10.2.6.1 Germany Blood Cancer Drugs Market-
10.2.6.1.1 Germany Blood Cancer Drugs Market- by Blood Cancer Types
10.2.6.1.2 Germany Blood Cancer Drugs Market- by Drugs
10.2.6.1.3 Germany Blood Cancer Drugs Market- by Treatment Approaches
10.2.6.2 France Blood Cancer Drugs Market-
10.2.6.2.1 France Blood Cancer Drugs Market- by Blood Cancer Types
10.2.6.2.2 France Blood Cancer Drugs Market- by Drugs
10.2.6.2.3 France Blood Cancer Drugs Market- by Treatment Approaches
10.2.6.3 Italy Blood Cancer Drugs Market-
10.2.6.3.1 Italy Blood Cancer Drugs Market- by Blood Cancer Types
10.2.6.3.2 Italy Blood Cancer Drugs Market- by Drugs
10.2.6.3.3 Italy Blood Cancer Drugs Market- by Treatment Approaches
10.2.6.4 Spain Blood Cancer Drugs Market-
10.2.6.4.1 Spain Blood Cancer Drugs Market- by Blood Cancer Types
10.2.6.4.2 Spain Blood Cancer Drugs Market- by Drugs
10.2.6.4.3 Spain Blood Cancer Drugs Market- by Treatment Approaches
10.2.6.5 United Kingdom Blood Cancer Drugs Market-
10.2.6.5.1 United Kingdom Blood Cancer Drugs Market- by Blood Cancer Types
10.2.6.5.2 United Kingdom Blood Cancer Drugs Market- by Drugs
10.2.6.5.3 United Kingdom Blood Cancer Drugs Market- by Treatment Approaches
10.2.6.6 Rest of Europe Blood Cancer Drugs Market-
10.2.6.6.1 Rest of Europe Blood Cancer Drugs Market- by Blood Cancer Types
10.2.6.6.2 Rest of Europe Blood Cancer Drugs Market- by Drugs
10.2.6.6.3 Rest of Europe Blood Cancer Drugs Market- by Treatment Approaches
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Blood Cancer Drugs Market- Overview
10.3.2 Asia-Pacific Blood Cancer Drugs Market- Forecasts and Analysis
10.3.3 Asia-Pacific Blood Cancer Drugs Market- Forecasts and Analysis - By Blood Cancer Types
10.3.4 Asia-Pacific Blood Cancer Drugs Market- Forecasts and Analysis - By Drugs
10.3.5 Asia-Pacific Blood Cancer Drugs Market- Forecasts and Analysis - By Treatment Approaches
10.3.6 Asia-Pacific Blood Cancer Drugs Market- Forecasts and Analysis - By Countries
10.3.6.1 Australia Blood Cancer Drugs Market-
10.3.6.1.1 Australia Blood Cancer Drugs Market- by Blood Cancer Types
10.3.6.1.2 Australia Blood Cancer Drugs Market- by Drugs
10.3.6.1.3 Australia Blood Cancer Drugs Market- by Treatment Approaches
10.3.6.2 China Blood Cancer Drugs Market-
10.3.6.2.1 China Blood Cancer Drugs Market- by Blood Cancer Types
10.3.6.2.2 China Blood Cancer Drugs Market- by Drugs
10.3.6.2.3 China Blood Cancer Drugs Market- by Treatment Approaches
10.3.6.3 India Blood Cancer Drugs Market-
10.3.6.3.1 India Blood Cancer Drugs Market- by Blood Cancer Types
10.3.6.3.2 India Blood Cancer Drugs Market- by Drugs
10.3.6.3.3 India Blood Cancer Drugs Market- by Treatment Approaches
10.3.6.4 Japan Blood Cancer Drugs Market-
10.3.6.4.1 Japan Blood Cancer Drugs Market- by Blood Cancer Types
10.3.6.4.2 Japan Blood Cancer Drugs Market- by Drugs
10.3.6.4.3 Japan Blood Cancer Drugs Market- by Treatment Approaches
10.3.6.5 South Korea Blood Cancer Drugs Market-
10.3.6.5.1 South Korea Blood Cancer Drugs Market- by Blood Cancer Types
10.3.6.5.2 South Korea Blood Cancer Drugs Market- by Drugs
10.3.6.5.3 South Korea Blood Cancer Drugs Market- by Treatment Approaches
10.3.6.6 Rest of Asia-Pacific Blood Cancer Drugs Market-
10.3.6.6.1 Rest of Asia-Pacific Blood Cancer Drugs Market- by Blood Cancer Types
10.3.6.6.2 Rest of Asia-Pacific Blood Cancer Drugs Market- by Drugs
10.3.6.6.3 Rest of Asia-Pacific Blood Cancer Drugs Market- by Treatment Approaches
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Blood Cancer Drugs Market- Overview
10.4.2 Middle East and Africa Blood Cancer Drugs Market- Forecasts and Analysis
10.4.3 Middle East and Africa Blood Cancer Drugs Market- Forecasts and Analysis - By Blood Cancer Types
10.4.4 Middle East and Africa Blood Cancer Drugs Market- Forecasts and Analysis - By Drugs
10.4.5 Middle East and Africa Blood Cancer Drugs Market- Forecasts and Analysis - By Treatment Approaches
10.4.6 Middle East and Africa Blood Cancer Drugs Market- Forecasts and Analysis - By Countries
10.4.6.1 South Africa Blood Cancer Drugs Market-
10.4.6.1.1 South Africa Blood Cancer Drugs Market- by Blood Cancer Types
10.4.6.1.2 South Africa Blood Cancer Drugs Market- by Drugs
10.4.6.1.3 South Africa Blood Cancer Drugs Market- by Treatment Approaches
10.4.6.2 Saudi Arabia Blood Cancer Drugs Market-
10.4.6.2.1 Saudi Arabia Blood Cancer Drugs Market- by Blood Cancer Types
10.4.6.2.2 Saudi Arabia Blood Cancer Drugs Market- by Drugs
10.4.6.2.3 Saudi Arabia Blood Cancer Drugs Market- by Treatment Approaches
10.4.6.3 U.A.E Blood Cancer Drugs Market-
10.4.6.3.1 U.A.E Blood Cancer Drugs Market- by Blood Cancer Types
10.4.6.3.2 U.A.E Blood Cancer Drugs Market- by Drugs
10.4.6.3.3 U.A.E Blood Cancer Drugs Market- by Treatment Approaches
10.4.6.4 Rest of Middle East and Africa Blood Cancer Drugs Market-
10.4.6.4.1 Rest of Middle East and Africa Blood Cancer Drugs Market- by Blood Cancer Types
10.4.6.4.2 Rest of Middle East and Africa Blood Cancer Drugs Market- by Drugs
10.4.6.4.3 Rest of Middle East and Africa Blood Cancer Drugs Market- by Treatment Approaches
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Blood Cancer Drugs Market- Overview
10.5.2 South and Central America Blood Cancer Drugs Market- Forecasts and Analysis
10.5.3 South and Central America Blood Cancer Drugs Market- Forecasts and Analysis - By Blood Cancer Types
10.5.4 South and Central America Blood Cancer Drugs Market- Forecasts and Analysis - By Drugs
10.5.5 South and Central America Blood Cancer Drugs Market- Forecasts and Analysis - By Treatment Approaches
10.5.6 South and Central America Blood Cancer Drugs Market- Forecasts and Analysis - By Countries
10.5.6.1 Brazil Blood Cancer Drugs Market-
10.5.6.1.1 Brazil Blood Cancer Drugs Market- by Blood Cancer Types
10.5.6.1.2 Brazil Blood Cancer Drugs Market- by Drugs
10.5.6.1.3 Brazil Blood Cancer Drugs Market- by Treatment Approaches
10.5.6.2 Argentina Blood Cancer Drugs Market-
10.5.6.2.1 Argentina Blood Cancer Drugs Market- by Blood Cancer Types
10.5.6.2.2 Argentina Blood Cancer Drugs Market- by Drugs
10.5.6.2.3 Argentina Blood Cancer Drugs Market- by Treatment Approaches
10.5.6.3 Rest of South and Central America Blood Cancer Drugs Market-
10.5.6.3.1 Rest of South and Central America Blood Cancer Drugs Market- by Blood Cancer Types
10.5.6.3.2 Rest of South and Central America Blood Cancer Drugs Market- by Drugs
10.5.6.3.3 Rest of South and Central America Blood Cancer Drugs Market- by Treatment Approaches
11. IMPACT OF COVID-19 PANDEMIC ON GLOBAL BLOOD CANCER DRUGS MARKET-
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Middle East and Africa
11.5 South and Central America
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. BLOOD CANCER DRUGS MARKET-, KEY COMPANY PROFILES
13.1. JOHNSON AND JOHNSON INC.
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. AMGEN INC.
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. BAYER AG.
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. PFIZER, INC.
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. ABBVIE INC.
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. ROCHE HOLDING AG.
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. CELGENE CORPORATION
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. ASTRAZENECA
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. NOVARTIS AG
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. GLAXOSMITHKLINE PLC
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
1. Johnson & Johnson Inc.
2. Amgen Inc.
3. Bayer AG.
4. Pfizer, Inc.]
5. AbbVie Inc.
6. Roche Holding AG.
7. Celgene Corporation
8. AstraZeneca
9. Novartis AG
10. GlaxoSmithKline PLC
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For